Leo Wealth LLC Purchases 25,063 Shares of Sanofi $SNY

Leo Wealth LLC purchased a new stake in shares of Sanofi (NASDAQ:SNY) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 25,063 shares of the company’s stock, valued at approximately $1,033,000.

Other hedge funds also recently bought and sold shares of the company. Bank of America Corp DE raised its position in shares of Sanofi by 11.0% during the 1st quarter. Bank of America Corp DE now owns 9,484,350 shares of the company’s stock valued at $456,956,000 after buying an additional 940,342 shares in the last quarter. Mondrian Investment Partners LTD increased its stake in Sanofi by 2.3% during the third quarter. Mondrian Investment Partners LTD now owns 5,652,139 shares of the company’s stock worth $233,038,000 after acquiring an additional 129,575 shares during the last quarter. Royal Bank of Canada increased its stake in Sanofi by 17.5% during the first quarter. Royal Bank of Canada now owns 3,155,080 shares of the company’s stock worth $152,011,000 after acquiring an additional 470,882 shares during the last quarter. Regal Partners Ltd raised its position in Sanofi by 33.2% during the first quarter. Regal Partners Ltd now owns 2,545,432 shares of the company’s stock valued at $122,639,000 after purchasing an additional 633,782 shares during the period. Finally, Manning & Napier Advisors LLC raised its position in Sanofi by 728,134.8% during the first quarter. Manning & Napier Advisors LLC now owns 1,194,305 shares of the company’s stock valued at $57,542,000 after purchasing an additional 1,194,141 shares during the period. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Sanofi Stock Performance

Sanofi stock opened at $41.79 on Tuesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 0.99 and a quick ratio of 0.64. Sanofi has a 1-year low of $39.07 and a 1-year high of $52.68. The firm has a market capitalization of $101.32 billion, a P/E ratio of 21.88, a price-to-earnings-growth ratio of 1.28 and a beta of 0.33. The company’s 50-day moving average is $42.38 and its 200 day moving average is $44.46.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, July 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The business had revenue of $13.36 billion during the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The firm’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same period in the previous year, the business earned $3.24 EPS. Research analysts forecast that Sanofi will post 5.00 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Wolfe Research began coverage on Sanofi in a research note on Friday, October 9th. They issued a “peer perform” rating for the company. Jefferies Financial Group reissued a “buy” rating on shares of Sanofi in a research report on Thursday, October 1st. Wall Street Zen lowered Sanofi from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research report on Thursday, October 1st. Finally, DZ Bank reaffirmed a “buy” rating on shares of Sanofi in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $49.50.

Sanofi Profile

Sanofi is a France-based global healthcare company that researches, develops, manufactures and markets prescription medicines and vaccines. Its operations focus primarily on specialty medicines, immunology, rare diseases, neurology, oncology and treatments for rare blood disorders, as well as established pharmaceutical products.

The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron; vaccines for influenza, polio, meningitis and other infectious diseases; and treatments for conditions including multiple sclerosis, hemophilia and certain rare diseases.